Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mikako Tamba
Observed name:
Mikako TAMBA
Institutions:
The Cancer Institute Hospital,
Japanese Foundation For Cancer Research
Observed institutions:
The Cancer Institute Hospital,
Japanese Foundation For Cancer Research
ORCID:
0009-0006-1380-4325
Observed ORCID:
0009-0006-1380-4325
OpenAlex ID:
A5001536738
Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy
2023
·
Yuko Shirouchi
, Noriko Nishimura
, et al.
·
Scientific Reports
·
7
PDF
Serum cell-free DNA concentration as a possible prognostic marker in newly diagnosed diffuse large B-cell lymphoma
2022
·
Yuko SHIROUCHI
, Yuko MISHIMA
, et al.
·
Biomedical Research
·
7
PDF
Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings
2025
·
Koshiro Fukuda
, Hiroki Osumi
, et al.
·
Therapeutic Advances in Gastroenterology
·
4
Real-world safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma
2025
·
Mikako Tamba
, Hiroki Osumi
, et al.
·
BMC Cancer
·
4
PDF
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer
2026
·
Koichiro Yoshino
, Manabu Takamatsu
, et al.
·
Gastric Cancer
·
3
PDF
Investigating the role of immunotherapy for real-world patients with HER2-negative advanced gastric cancer between 2011 and 2023
2025
·
Keitaro Shimozaki
, Akira Ooki
, et al.
·
Therapeutic Advances in Medical Oncology
·
3
Clinicopathological characteristics and survival in metastatic colorectal cancer with short-form APC mutations.
2024
·
Hiroki Osumi
, Akira Ooki
, et al.
·
Journal of Clinical Oncology
·
3
PDF
Impact of early tumor shrinkage and depth of response in patients with BRAF V600E-mutant metastatic colorectal cancer
2025
·
Shohei Udagawa
, Hiroki Osumi
, et al.
·
International Journal of Clinical Oncology
·
2
Pb2317: Polatuzumab Vedotin Plus Bendamustine and Rituximab Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma: a Single-institution Experience Focusing on Detailed Assessment of Toxicities
2023
·
Mitsuhito Hirano
, Kikuaki Yoshida
, et al.
·
HemaSphere
·
2
Durable response of therapy-related MDS/AML with concomitant Waldenström’s macroglobulinemia treated with venetoclax and azacitidine
2022
·
Mitsuhito Hirano
, Mikako Tamba
, et al.
·
Annals of Hematology
·
2
PDF
Association of early tumor shrinkage with survival in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan.
2025
·
Koshiro Fukuda
, Akira Ooki
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Safety and tolerability of different total neoadjuvant therapy strategies in patients with locally advanced rectal cancer.
2025
·
Shohei Udagawa
, Hiroki Osumi
, et al.
·
Journal of Clinical Oncology
·
1
What is the optimal treatment strategy of salvage line treatment after progression on anti-epidermal growth factor receptor monoclonal antibody in patients with tissue RAS/BRAF wild-type metastatic colorectal cancer?
2025
·
Emiko Tange
, Hiroki Osumi
, et al.
·
Journal of Clinical Oncology
·
1
Impact of early tumor shrinkage and depth of response in patients with BRAF V600E-mutant metastatic colorectal cancer.
2024
·
Shohei Udagawa
, Hiroki Osumi
, et al.
·
Journal of Clinical Oncology
·
1
P33-7 Two patients with DLBCL who developed aortitis following pegfilgrastim administration during chemoimmunotherapy
2023
·
Mikako Tamba
, Hiroaki Asai
, et al.
·
Annals of Oncology
·
1
PDF
High-dose dexamethasone and prolonged infusion time prevent oxaliplatin-related hypersensitivity reactions in patients with metastatic colorectal cancer
2026
·
Koichiro Yoshino
, Hiroki Osumi
, et al.
·
International Journal of Clinical Oncology
PDF
C-reactive Protein to Albumin Ratio as a Prognostic Biomarker in Patients with Esophageal Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitor- based Therapy
2026
·
Koichiro Yoshino
, Akihiko Okamura
, et al.
·
Research Square
PDF
The role of immunotherapy for real-world patients with HER2-negative advanced gastric cancer between 2011-2023.
2025
·
Keitaro Shimozaki
, Akira Ooki
, et al.
·
Journal of Clinical Oncology
PDF
Lymph-node ratio as a risk factor for recurrence following neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma
2025
·
Mikako Tamba
, Akihiko Okamura
, et al.
·
Esophagus
Safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (Neo DCF) therapy for locally advanced esophageal cancer: Real world data analysis.
2024
·
Mikako Tamba
, Hiroki Osumi
, et al.
·
Journal of Clinical Oncology
PDF
Show more works
View as search
Works count:
20
Citation count:
42
H-index:
4
I10-index:
Year
Topic
Type